BS01 in Patients With Retinitis Pigmentosa

Launched by BIONIC SIGHT LLC · Feb 18, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called BS01 for people with a condition known as retinitis pigmentosa, which affects vision by damaging the light-sensitive cells in the retina of the eye. The trial aims to see if BS01, a specially designed virus that carries a gene to improve light sensitivity in the retina, can help patients who have very limited vision (bare light perception) in at least one eye. This is a Phase 1/2 study, meaning it’s one of the first steps in testing this treatment to ensure it is safe and to find the right dose.

To participate in this trial, individuals must have a confirmed diagnosis of retinitis pigmentosa and be between the ages of 65 and 74. However, people who have previously received gene therapy or have a specific type of eye movement disorder called large amplitude nystagmus are not eligible to join. If you qualify and decide to participate, you can expect to receive the BS01 treatment and help researchers learn more about its effects on vision. This study is currently recruiting participants, and your involvement could contribute to important advancements in treating this eye condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of retinitis pigmentosa
• • Bare light perception in at least one eye
• Exclusion Criteria:
• • Prior receipt of any AAV gene therapy product
• • Large amplitude nystagmus